Mágnesesrezonancia-képalkotas alemtuzumab- és teriflunomidkezelés során

Translated title of the contribution: Magnetic resonance imaging in the course of alemtuzumab and teriflunomide therapy

Andrea Mike, Zsigmond Tamás Kincses, L. Vécsei

Research output: Contribution to journalReview article

Abstract

Our work aimed to review the published results of magnetic resonance imaging (MRI) obtained in the course of alemtuzumab and teriflunomide therapy in multiplex sclerosis. In multiplex sclerosis MRI sensitively detects subclinical pathological processes, which do not manifest clinically in the early course of the disease, however have substantial significance from the viewpoint of the long-term disease prognosis. MRI has an increasingly important role in the early monitoring of the therapeutic efficacy. In the last 15 years several clinical trials have been conducted with alemtuzumab and teriflunomide in multiple sclerosis providing evidence about the favourable clinical effect of these drugs. MRI images were acquired in these trials as well, and the results published recently in the scientific literature. These MRI results denote the suppression of the disease activity and the neurodegenerative processes, which may imply a favourable effect on the long-term prognosis of the disease.

Original languageHungarian
Pages (from-to)15-24
Number of pages10
JournalIdeggyogyaszati Szemle
Volume70
Issue number1-2
DOIs
Publication statusPublished - Jan 30 2017

Fingerprint

Magnetic Resonance Imaging
Sclerosis
Literature
Therapeutics
Pathologic Processes
Neurodegenerative Diseases
Multiple Sclerosis
alemtuzumab
teriflunomide
Clinical Trials
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Mágnesesrezonancia-képalkotas alemtuzumab- és teriflunomidkezelés során. / Mike, Andrea; Kincses, Zsigmond Tamás; Vécsei, L.

In: Ideggyogyaszati Szemle, Vol. 70, No. 1-2, 30.01.2017, p. 15-24.

Research output: Contribution to journalReview article

Mike, Andrea ; Kincses, Zsigmond Tamás ; Vécsei, L. / Mágnesesrezonancia-képalkotas alemtuzumab- és teriflunomidkezelés során. In: Ideggyogyaszati Szemle. 2017 ; Vol. 70, No. 1-2. pp. 15-24.
@article{9c1d705af88f45e38846d4fbc1bb2c79,
title = "M{\'a}gnesesrezonancia-k{\'e}palkotas alemtuzumab- {\'e}s teriflunomidkezel{\'e}s sor{\'a}n",
abstract = "Our work aimed to review the published results of magnetic resonance imaging (MRI) obtained in the course of alemtuzumab and teriflunomide therapy in multiplex sclerosis. In multiplex sclerosis MRI sensitively detects subclinical pathological processes, which do not manifest clinically in the early course of the disease, however have substantial significance from the viewpoint of the long-term disease prognosis. MRI has an increasingly important role in the early monitoring of the therapeutic efficacy. In the last 15 years several clinical trials have been conducted with alemtuzumab and teriflunomide in multiple sclerosis providing evidence about the favourable clinical effect of these drugs. MRI images were acquired in these trials as well, and the results published recently in the scientific literature. These MRI results denote the suppression of the disease activity and the neurodegenerative processes, which may imply a favourable effect on the long-term prognosis of the disease.",
keywords = "Alemtuzumab, MRI, Multiple sclerosis, Teriflunomide",
author = "Andrea Mike and Kincses, {Zsigmond Tam{\'a}s} and L. V{\'e}csei",
year = "2017",
month = "1",
day = "30",
doi = "10.18071/isz.70.0015",
language = "Hungarian",
volume = "70",
pages = "15--24",
journal = "Ideggyogyaszati Szemle",
issn = "0019-1442",
publisher = "Ifjusagi Lap-es Konyvkiado Vallalat",
number = "1-2",

}

TY - JOUR

T1 - Mágnesesrezonancia-képalkotas alemtuzumab- és teriflunomidkezelés során

AU - Mike, Andrea

AU - Kincses, Zsigmond Tamás

AU - Vécsei, L.

PY - 2017/1/30

Y1 - 2017/1/30

N2 - Our work aimed to review the published results of magnetic resonance imaging (MRI) obtained in the course of alemtuzumab and teriflunomide therapy in multiplex sclerosis. In multiplex sclerosis MRI sensitively detects subclinical pathological processes, which do not manifest clinically in the early course of the disease, however have substantial significance from the viewpoint of the long-term disease prognosis. MRI has an increasingly important role in the early monitoring of the therapeutic efficacy. In the last 15 years several clinical trials have been conducted with alemtuzumab and teriflunomide in multiple sclerosis providing evidence about the favourable clinical effect of these drugs. MRI images were acquired in these trials as well, and the results published recently in the scientific literature. These MRI results denote the suppression of the disease activity and the neurodegenerative processes, which may imply a favourable effect on the long-term prognosis of the disease.

AB - Our work aimed to review the published results of magnetic resonance imaging (MRI) obtained in the course of alemtuzumab and teriflunomide therapy in multiplex sclerosis. In multiplex sclerosis MRI sensitively detects subclinical pathological processes, which do not manifest clinically in the early course of the disease, however have substantial significance from the viewpoint of the long-term disease prognosis. MRI has an increasingly important role in the early monitoring of the therapeutic efficacy. In the last 15 years several clinical trials have been conducted with alemtuzumab and teriflunomide in multiple sclerosis providing evidence about the favourable clinical effect of these drugs. MRI images were acquired in these trials as well, and the results published recently in the scientific literature. These MRI results denote the suppression of the disease activity and the neurodegenerative processes, which may imply a favourable effect on the long-term prognosis of the disease.

KW - Alemtuzumab

KW - MRI

KW - Multiple sclerosis

KW - Teriflunomide

UR - http://www.scopus.com/inward/record.url?scp=85014653781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014653781&partnerID=8YFLogxK

U2 - 10.18071/isz.70.0015

DO - 10.18071/isz.70.0015

M3 - Review article

C2 - 29870189

AN - SCOPUS:85014653781

VL - 70

SP - 15

EP - 24

JO - Ideggyogyaszati Szemle

JF - Ideggyogyaszati Szemle

SN - 0019-1442

IS - 1-2

ER -